Larotrectinib, a selective inhibitor of tropomyosin receptor kinase, has been effective in pediatric tumors with Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion mutations in children as young as 1-month-old.
Offenbacher et al. shared the case of a 9-month-old boy who presented with a 4-month history of regression of his milestones and severe constipation who was found to have a large spinal pilocytic astrocytoma with multiple intracranial periventricular lesions 1)